Current Assets
Income taxes receivable
Pfizer Income taxes receivable increased by 2.9% to $3.97B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 19.7%, from $3.31B to $3.97B. Over 5 years (FY 2020 to FY 2025), Income taxes receivable shows an upward trend with a 4.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalHigher is better
VolatilityModerate
First reportedQ4 2015
Last reportedQ1 2026
How to read this metric
An increase may indicate overpayment of estimated taxes or the accrual of refundable credits, representing a potential source of near-term cash inflow.
Detailed definition
This represents the amount of income tax overpayments or refundable tax credits that the company expects to recover from...
Peer comparison
Common for large corporations that manage complex tax filings across multiple jurisdictions.
Metric ID:
income_taxes_receivableHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.76B | $3.88B | $4.27B | $3.12B | $2.58B | $2.54B | $3.58B | $3.14B | $3.19B | $3.92B | $3.98B | $4.23B | $3.69B | $3.24B | $3.31B | $2.90B | $4.02B | $3.86B | $3.97B |
| QoQ Change | — | +3.1% | +10.0% | -26.9% | -17.1% | -1.5% | +40.6% | -12.2% | +1.7% | +22.6% | +1.6% | +6.4% | -12.7% | -12.2% | +2.2% | -12.5% | +38.5% | -4.0% | +2.9% |
| YoY Change | — | — | — | — | -31.3% | -34.4% | -16.2% | +0.7% | +23.7% | +54.0% | +11.2% | +34.8% | +15.7% | -17.2% | -16.7% | -31.5% | +8.7% | +18.9% | +19.7% |
Range$2.54B – $4.27B
CAGR+1.2%
Avg YoY Growth+2.7%
Median YoY Growth+8.7%
Income taxes receivable at Other Companies
Frequently Asked Questions
- What is Pfizer's income taxes receivable?
- Pfizer (PFE) reported income taxes receivable of $3.97B in Q4 2025.
- How has Pfizer's income taxes receivable changed year-over-year?
- Pfizer's income taxes receivable increased by 19.7% year-over-year, from $3.31B to $3.97B.
- What is the long-term trend for Pfizer's income taxes receivable?
- Over 5 years (2020 to 2025), Pfizer's income taxes receivable has grown at a 4.0% compound annual growth rate (CAGR), from $3.26B to $3.97B.
- What does income taxes receivable mean?
- Tax refunds or credits owed to the company by government tax agencies.